SUMMARY
from mother's milk across the gut endothelium of rodents. 7 We also report the sustained restoration of sweating ability in three human patients with XLHED in response to prenatal treatment with Fc-EDA.
CASE REPORTS

Patients 1 and 2
A 38-year-old pregnant woman referred to us in gestational week 22 with a family history of XLHED was concerned that the twins she was carrying would be affected. Her older son had the disease, including a complete absence of sweat pores and sweating; genetic testing revealed hemizygosity for the EDA mutation c.911A>G (p.Y304C). Y304 mediates trimerization of EDA and its replacement by cysteine abrogates secretion of the protein (Fig.   S1 ). The mother was confirmed to be a heterozygous carrier of this mutation.
Ultrasonographic examination showed a twin pregnancy (monochorionic, diamniotic) with two male fetuses, both lacking tooth germs (no tooth germs at all in the lower jaw and one or two, respectively, in the upper jaw; normally 9-10 tooth germs per jaw are seen). 10 Apart from that, no anomalies were evident. Additional magnetic resonance imaging confirmed the ultrasonographic findings and supported a diagnosis of XLHED in both twins.
Inability to sweat, the most severe clinical problem of XLHED patients, can lead to lifethreatening hyperthermia after birth. [11] [12] [13] Knowing that human sweat glands form between gestational weeks 20 and 30, 14 that sweat gland development was not rescued by administration of Fc-EDA to XLHED patients shortly after birth (NCT01775462;
www.clinicaltrials.gov), and that delivery of Fc-EDA into the amniotic cavity prevented XLHED in rodents, direct intra-amniotic drug administration at the appropriate stages of development appeared to be a promising therapeutic approach. We hypothesized that amniotic fluid would serve as a reservoir of Fc-EDA: the size of the protein would limit its diffusion from the amniotic cavity and allow its uptake from the fetal gut via drinking amniotic fluid.
Compassionate use of Fc-EDA requested by the parents of the affected twins was taken into consideration and finally approved by the clinical ethics committee of the University Hospital Erlangen. Written informed consent to intra-amniotic administration of Fc-EDA was obtained. Treatment was to be performed by amniocentesis at week 26 of gestation under ultrasound guidance with the same batch of Fc-EDA used in clinical trial NCT01775462. The planned procedure included withdrawal of 15 ml of amniotic fluid, followed by injection of Fc-EDA (100 mg/kg of estimated fetal body weight) in a 15-ml sterile solution into the amniotic cavity of each fetus (at 26 weeks the volume of amniotic fluid usually exceeds 500 ml). A second administration of the drug at 31 weeks of gestation was considered. EDA concentrations in serum (pregnant women, treated children) and amniotic fluid samples were to be determined by MPI Research Inc. (Mattawan, USA).
MECHANISM OF DRUG UPTAKE IN A RODENT MODEL
Fc-EDA is a recombinant fusion protein consisting of the receptor-binding domain of EDA (100% conserved between mouse and human proteins) and the Fc domain of human immunoglobulin G1 (EDI200, Edimer Pharmaceuticals). When administered at doses of approximately 100 mg/kg into the amniotic fluid of male Eda Y/-mice and also Eda -/-mice (both sexes) at embryonic day 14.5 (E14.5), Fc-EDA prevented the development of XLHED.
In contrast, administration of a control protein made up of the same domain of EDA but fused to the collagen-like domain of adiponectin did not prevent XLHED, except for two cases (in 1 of 3 pregnancies), which could be explained by accidental introduction of the fusion protein into the fetal bloodstream through damage to the fetus or a peripheral yolk sac vessel with the injection needle ( Table 1, Table S1 ). Furthermore, EDA-deficient fetuses that were also devoid of the neonatal Fc receptor were not corrected by Fc-EDA at E13.5, while all fetuses expressing the neonatal Fc receptor in the same litter were corrected: they developed into mice that did not exhibit the disease phenotype ( Table 1 ). The same was true for treatment at E12.5, except that structures (for example, guard hair) forming close to the time of injection were rescued more efficiently than those (such as tail hair and sweat ducts) forming at later stages of development (Table 1 , Fig. S2 ).
Because Fc-EDA rescued normal development only in the presence of intact neonatal Fc receptor, the therapeutic route of Fc-EDA is systemic rather than through a direct effect on the skin and oral epithelia. Moreover, the milk of dams who received an intraperitoneal injection of agonist anti-EDAR antibody (mAbEDAR1) at days 1, 2 or 3 of lactation tested positive for the antibody (Fig. S3 ). Normal development of EDA-deficient pups fed on this milk occurred only if they expressed the neonatal Fc receptor, indicative of neonatal Fc receptor-mediated uptake of this antibody in the gut (Table 1) . 8 Bypassing the need for transport mediated by the neonatal Fc receptor through direct intraperitoneal administration of mAbEDAR1 to newborn pups rescued normal development: the efficacy of rescue was the same, regardless of whether the neonatal Fc receptor was expressed (Fig. S4 ). In contrast, intraperitoneal delivery of Fc-EDA to EDA-deficient animals had much stronger effects on neonatal Fc receptor-positive pups than on pups devoid of it (Fig. S4 ). This is consistent with the dramatic difference in serum half-life of Fc-EDA after intravenous injection in adult mice with a single wild-type allele of the neonatal Fc receptor (48 hours) and in adult mice completely deficient of this receptor (22 minutes).
The serum half-life of mAbEDAR1 was comparatively longer: 10 days in adult mice with a single wild-type allele of the neonatal Fc receptor and one day in null mice. Possibly the surprising efficacy of mAbEDAR1 in the absence of neonatal Fc receptor can be explained by the fact that exposure to EDAR agonists (delivered via intraperitoneal injection)
for only 4 hours is sufficient to permanently correct the tail hair phenotype in newborn EDA-deficient mice 9 and because mAbEDAR1, once bound to EDAR, dissociates from it very slowly. 5 We concluded from these experiments that Fc-EDA provided in amniotic fluid must first enter the organism in a manner dependent on the neonatal Fc receptor, presumably via the gut, before it can act on developing EDA-dependent structures. Increased serum half-life of Fc-EDA in the presence of the neonatal Fc receptor further enhances treatment efficacy.
PRECLINICAL TESTING IN PRIMATES
Prior to the decision on compassionate use of Fc-EDA in human fetuses, toxicity studies had been conducted in cynomolgus monkeys (twice weekly intravenous infusion of Fc-EDA over three weeks followed by a 15-day recovery period). We did not observe signs of toxicity, including at the highest dose (100 mg/kg body weight). Another study in pregnant monkeys
showed that transplacental passage of Fc-EDA after intravenous administration to the mother occurred in primates only at very low levels (<1% of concurrent maternal serum concentrations) during the equivalent of human third trimester (Table S2 ), suggesting that drug delivery to primate fetuses via the maternal circulation may not be an adequate method.
CASE REPORTS (continued)
Patients 1 and 2
In February 2016, at week 26 of gestation, the affected twins were treated in utero. An amniocentesis of both amniotic cavities was performed to obtain amniotic fluid for genetic testing and to inject Fc-EDA at a dose of 100 mg/kg estimated fetal body weight. In the hours after administration and the following day no Fc-EDA was detectable in the circulation of the pregnant woman. Subsequent fetal development was uncomplicated. Genetic testing confirmed hemizygosity of both twins for the EDA Y304C mutation. At week 31, 39 days after the first Fc-EDA administration, we injected a second dose of Fc-EDA (100 mg/kg estimated fetal body weight). Assays of Fc-EDA in the amniotic fluid withdrawn prior to the second injection gave a null result.
Due to premature labor the treated twins were born prematurely by caesarian section at gestational week 32 0/7 with birth weights of 1705 and 1615 grams and Apgar scores of 8/9/9 and 9/10/10, respectively. Although clinical assessment after birth did not reveal signs of infection, both neonates received antibiotics for 5 days. The neonatal course was unremarkable. In cord blood samples (one from each twin), Fc-EDA was still detectable 7
days after administration at concentrations of 62.4 and 932 ng/mL, suggesting that it had been taken up continuously from amniotic fluid into the fetal blood. The treated infants showed a normal sweat-duct density 15 on the soles of the feet (Fig. 1a, c ) and normal pilocarpineinduced sweating (Fig. 1b, d ). Various body parts were repeatedly observed to be moist. Both 2), compared with 3 teeth and one additional tooth germ in their untreated brother.
Patient 3
Another pregnant woman who had a son with XLHED was referred to us at week 19 of gestation. Ultrasonography of her male fetus showed an obvious lack of tooth germs. Pilocarpine-induced sweat production at 6 months of age was lower than in the treated twins ( Fig. 1d) , suggesting a slower maturation of sweat gland function. 16 . In contrast to untreated male XLHED patients who have no more than three Meibomian glands per eyelid, 17 this treated boy showed a near-normal number of Meibomian glands (15 and 11 gland ducts per lower eyelid). 17 In the oral cavity X-ray imaging revealed the presence of 9 tooth germs; his older brother had only two tooth buds
DISCUSSION
Prenatal treatment with Fc-EDA restored sustained sweating ability in human patients with EDA mutations that abrogate perspiration. As yet the treated children, who are now 14 to 22 months old, have not been reported to have experienced any hyperthermic episodes nor have they had respiratory-related hospitalizations. Premature labor and preterm birth were severe adverse events. We note that most twins are born preterm and 20% are delivered before 34 weeks of gestation in the absence of prenatal procedures. 18 The other adverse events of both women and their children were moderate or mild (Table S3 ). Signs of effects on tooth development and salivary and Meibomian glands have been observed in the treated infants, in comparison with the phenotypes of their untreated affected siblings. We do not know whether the therapeutic effects are permanent. We have, however, observed permanent effects in mouse and dog models. [4] [5] [6] 19, 20 Although the rate of amniocentesis-related miscarriage is only 0.11%, 21 Fc-EDA was not delivered before week 26 of gestation. We reasoned that, if inadvertent rupture of membranes occurred at that time, it would probably be possible to prolong the pregnancy for several days or even weeks. 22 In our opinion, the prospects of higher efficacy that could be obtained through earlier treatment do not outweigh even a very low risk quoad vitam. Nevertheless, any pre-term birth caused by the procedure would be associated with risks to baby and mother (increased neonatal morbidity and mortality, and maternal infection).
In summary, we identified a mechanism of drug uptake into fetuses resulting in effective treatment of a genetic disability, albeit in a very small sample (two pregnancies) and with limited follow-up of the live-born infants. Combined with the ability to identify affected individuals by non-invasive sonographic prenatal screening, 23 the approach we describe here represents a new means of protein replacement therapy to correct XLHED.
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We are grateful to Elisabeth Koppmann (University of Erlangen-Nürnberg), Aubry Tardivel Table 1 . Phenotypic reversion of EDA-deficient mice following drug administration Teeth score (excluding the third molar): 0 = narrow molars, shallow cusps, no or rudimentary anterior cusp on the first molar (M1); 1 = wider molars, more defined cusps, one small anterior cusp on M1; 2 = wide molars, well-defined cusps, stubby anterior cusp on M1; 3 = like 2, but elongated anterior cusp on M1 (making ~1/3 of the length). Guard hair score (evaluated on a photography of the back of the mouse): 0 = no guard hair; 1 = between one and five guard hairs visible; 2 = sparse guard hair; 3 = numerous guard hairs all over the picture. Ear hair (skin area at the rear side of the ears evaluated): 0 = no hair, naked skin; 1 = very few hairs; 2 = sparse hair; 3 = dense hair, skin covered. Tail hair: 0 = none; 1 = sparse and only on one side of the tail; 2 = hair on both sides of the tail, usually dense on one side and sparse on the other; 3 = dense hair on both sides of the tail. Sweat ducts (evaluated on a photography of the paw showing all six foot pads after starch-iodine staining): 0 = no sweat spot; 1 = few spots on at least one foot pad; 2 = several spots on three or more foot pads; 3 = numerous sweat spots on at least five foot pads. i.a., intra-amniotic; i.p., intraperitoneal; n. . Anti-EDAR agonist antibody number 1 (mAbEDAR1) and hEDAR-hFc were generated as described. 2 Anti-EDA monoclonal antibody Renzo-2 is commercially available (Enzo Life Sciences).
TABLES
Plasmids coding for Flag-EDA (wild-type and Y304C) were transiently transfected in 293T cells that were then washed and cultured for 6 days in serum-free OptiMEM medium. Cells and supernatants were harvested and analyzed by SDS-PAGE and Western blot with anti-EDA antibody Renzo-2 essentially as described. 3 Sequences of proteins used are detailed in Table S2 . 
Genotyping
Experimental procedures on animals
Intra-amniotic administration of ACRP-EDA or Fc-EDA to mice at different time points of gestation was performed as described previously. 4 In some cases, Fc-EDA or mAbEDAR1 were injected intraperitoneally at doses of 10 mg/kg into dams within 24 hours after delivery and on the two days thereafter (at P1, P2 and P3). Fc-EDA, ACRP-EDA or mAbEDAR1 were also administered intraperitoneally to newborn pups on the day of birth at the doses indicated. The treated mice were investigated postnatally for various morphological features (tail and coat hair, presence of sweat ducts at the foot pads, shape of the molars). Starch-iodine sweat tests were performed as described previously. 4 For half-life determination, 200 µg of Fc-EDA or mAbEDAR1 were injected into the tail veins of adult mice. Serum was obtained from single drops of blood collected from cheek veins at the time points indicated.
Milk was taken from mice at days 2, 3 or 4 of lactation by gentle liquid aspiration from nipples with the plastic tubing (catheter) of a butterfly needle attached to a collection tube, itself connected to a cell culture vacuum pump (set at low suction power to enable sensitive aspiration). Lactating mice were treated by intraperitoneal injection of two units of oxytocin (03251-500U, Sigma-Aldrich) two minutes before milking.
Fc-EDA was also administered intravenously to cynomolgus monkeys. A group of three male and three female monkeys and a second group of five males and five females were treated by twice weekly infusion of Fc-EDA at dose levels of 30 or 100 mg/kg/dose, respectively, for three
weeks. An additional group of five animals of each sex which received the vehicle, 20 mM sodium phosphate, 300 mM sodium chloride, pH 7.2, and 0.02% Polysorbate 20 (w/v), served as control. The dose volume for all groups was 20 mL/kg/dose (10 mL/kg/hour). Following the treatment period, some animals were maintained for a 15-day recovery period. Observations regarding morbidity, mortality, injury, and the availability of food and water were conducted twice daily for all animals. Clinical observations took place twice weekly during the treatment period and weekly during recovery. Body weights were measured and recorded weekly.
Ophthalmoscopic examinations were conducted before drug delivery and prior to each scheduled necropsy. Electrocardiography was done on day 15 and prior to post-recovery necropsy. Blood samples for determination of the serum concentrations of EDA were collected from all animals on days 1 and 19 and prior to the post-recovery necropsy. The toxicokinetic parameters were determined for the drug from concentration-time data in the test species. Blood samples for evaluations of immunogenicity and blood and urine samples for further evaluations were obtained before drug delivery and prior to the necropsies. At the necropsies, examinations were performed, organ weights were recorded, and tissues were examined microscopically.
To evaluate the potential placental transfer of the drug, five pregnant monkeys received Fc-EDA intravenously at doses of 10, 30, and 100 mg/kg body weight and were sacrificed one to 12 hours later. Observations of the animals included clinical signs, body weights, heart rate, respiration rate, and body temperature. A toxicokinetic assessment was made.
Protein quantification by ELISA
Fc-EDA in 100 µl of 133-fold diluted sera (and 2-fold dilutions thereof) was quantified using ELISA plates coated with 100 µl of hEDAR-mFc (1 µg/ml) per well and revealed with a peroxidase-coupled anti-human IgG antibody; mAbEDAR1 was quantified similarly on hEDARhFc-coated plates and revealed with a peroxidase-coupled anti-mouse IgG antibody. Details of the ELISA procedure have been published. 5 EC50 was determined using the "log(agonist) vs.
normalized response -variable slope" function of Prism software.
Prenatal treatment of human patients
In three cases of male human fetuses with the prenatal diagnosis of XLHED (two monochorionic twins and a single fetus), written informed consent for prenatal intra-amniotic administration of 
Investigation of untreated affected siblings and other control subjects
The older brother of the treated twins who also carries the EDA mutation Y304C was investigated in parallel to his siblings. He had suffered several hyperthermic episodes in early infancy and was enrolled in the natural history study ECP-015 (ClinicalTrials.gov NCT02099552). The older brother of the third treated patient carries the EDA mutation V309GfsX8. He had been referred to the University Hospital Erlangen because of his characteristic facial appearance and repeated occurrence of unexplained fever soon after birth and was also investigated in parallel to his sibling. Three more boys and one male adult with the EDA mutation Y304C who had been examined in previous studies [6] [7] [8] or seen at the University Hospital Erlangen served as additional controls. Samples of healthy control subjects age-matched to the treated infants were investigated by confocal laser-scanning microscopy (n = 6) and quantification of pilocarpine-induced sweating (n = 6) at the University Hospital Erlangen.
Unstimulated saliva flow was determined in the treated twins, their older brother and two healthy 2-year-old infants. The adult provided written informed consent to participate in the study; in the case of minors, parental consent and if possible assent of the child were obtained.
Confocal laser-scanning microscopy
Reflectance confocal laser-scanning microscopy of skin areas of 36 mm² to determine sweat pore densities was conducted with a VivaScope 1500 (Caliber Imaging & Diagnostics, New York, USA) according to the manufacturer's instructions. The dermal ridges of the infants treated in utero were investigated in comparison with older siblings and healthy control infants.
Quantification of pilocarpine-induced sweating
Sweat was collected by a standardized procedure from an area of 57 mm² of the right or left forearm 30 min after stimulation with a pilocarpine gel disk using the Wescor 3700 device (Wescor, Logan, USA). Maximum volume that could be collected in this device was 93 µL. The volume was determined immediately after sampling.
Quantification of saliva flow
Whole saliva was collected with the Quantisal oral fluid collection device (Immunalysis, Pomona, USA) between 10:00 and 13:00 hours, after the subjects had refrained from eating and drinking for a period of 1 hour. All infants were instructed to swallow once before the test started and told to refrain from swallowing or talking during saliva collection for a total of 120 seconds.
The pre-weighted fluid collector was positioned under the tongue, and the head of the subject was kept down to allow gravity to help with fluid collection. In none of the tests the volume limit indicator turned blue during the procedure. After the collection period, the weight increase of the collector was determined on a special accuracy weighing machine (Sartorius Lab Instruments, Göttingen, Germany), and the saliva flow rate was calculated in mL/min. Oral fluid collection was repeated three times at different days or with intervals of at least 40 minutes.
Dental imaging
In the treated twins, magnetic resonance imaging (MRI) of the head was conducted at the age of two months. Dental radiography was done when the infants were 6 to 12 months old (age corrected for preterm birth).
Data availability
The datasets generated and/or analyzed during the current study are either included in this article (and its Supplementary appendix) or available from a data depository (DOI: 10.5281/zenodo.1164154), or will be provided by the corresponding author on reasonable request. Figure S1 . EDA mutation Y304C grossly affects solubility of the protein. a, Position of tyrosine 304 (Y304) in the crystal structure of the C-terminal TNF-homology domain of EDA (pdb accession number 1RJ7) in a top view of the homotrimeric protein. Y304 is situated at the interface of adjacent protomers in the crystal structure. b, same as panel a, but viewed from the side. In this representation, the receptor-expressing cell would be at the bottom of the picture. c, Flag-EDA1-WT (wild-type) and Flag-EDA1-Y304C were expressed as recombinant proteins in 293T cells and detected in cell extracts and conditioned culture medium by Western blot using the anti-EDA monoclonal antibody Renzo-2. Although Flag-EDA1-Y304C is expressed, none was found to be secreted. The black and white arrowheads point at the non-and mono-Nglycosylated forms of Flag-EDA1, respectively. 
SUPPLEMENTARY FIGURES
Figure S4. Efficacy of EDAR agonists to correct tail hair and sweat glands in EDAdeficient mice in the presence or absence of neonatal Fc receptor (FcRn).
Mice of the indicated genotypes were treated at birth with the indicated doses of mAbEDAR1 or Fc-EDA. Tail hair and sweating ability were scored three weeks later. Fcgrt is the gene encoding FcRn. After exclusion of the results indicated in brackets, the average reversion score for each treatment dose was used to determine EC50. The curve was manually superimposed on graphs. a, mAbEDAR1 in pups heterozygous for FcRn. b, mAbEDAR1 in FcRn-deficient pups. c, Fc-EDA in pups wild-type for FcRn. d, Fc-EDA in pups heterozygous for FcRn. e, Fc-EDA in FcRn-deficient pups. Male twins with the EDA mutation Y304C who had both received prenatal Fc-EDA treatment were investigated repeatedly after birth. a, Wet baby car seat of one of the treated twins in the summer documenting unstimulated sweating (spillage of urine or other liquids could be excluded). b, Assessment of salivation at the age of 21 months (together with the untreated affected brother). Saliva collected over a period of 120 seconds was quantified gravimetrically. All samples were obtained between 10:00 and 13:00 hours, after the subjects had refrained from eating and drinking for a period of 1 hour. Each column shows the average of three independent measurements, error bars indicate the standard deviation. Teeth score (excluding the third molar): 0 = narrow molars, shallow cusps, no or rudimentary anterior cusp on molar number 1 (M1); 1 = wider molars, more defined cusps, one small anterior cusp on M1; 2 = wide molars, well-defined cusps, stubby anterior cusp on M1; 3 = like 2, but elongated anterior cusp on M1 (making ~1/3 of the length). Guard hair score (evaluated on a photography of the back of the mouse): 0 = no guard hair; 1 = between one and five guard hairs visible; 2 = sparse guard hair; 3 = numerous guard hairs all over the picture. Ear hair (skin area at the rear side of the ears evaluated): 0 = no hair, naked skin; 1 = very few hairs; 2 = sparse hair; 3 = dense hair, skin covered. Tail hair: 0 = none; 1 = sparse and only on one side of the tail; 2 = hair on both sides of the tail, usually dense on one side and sparse on the other; 3 = dense hair on both sides of the tail. Sweat ducts (evaluated on a photography of the paw showing all six foot pads after starch-iodine staining): 0 = no sweat spot; 1 = few spots on at least one foot pad; 2 = several spots on three or more foot pads; 3 = numerous sweat spots on at least five foot pads. i.a., intra-amniotic; i.p., intraperitoneal; n.d., not determined; *, partial reversion observed in these animals might have been due to accidental damage of the foetus or a yolk sac vessel during the injection procedure. Table S2 . EDA serum concentrations after intravenous infusion administration of Fc-EDA to pregnant monkeys.
SUPPLEMENTARY TABLES
NA, not applicable. Standard deviation (SD) and coefficient of variation (CV) are not reported, when mean concentration equals zero or n<3. 
